삼천당제약

000250KOSDAQ의약품 제조업

43.8 / 100

Reference Date: 2026-07-24

Financial Score8.5 / 40

News Sentiment18.3 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, PER raises overvaluation concerns. Plunged 30.4% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Samcheon Pharmaceutical, established in 1943, is a leading manufacturer and distributor of prescription pharmaceuticals, specializing in antibiotics, cardiovascular treatments, digestive system medications, and ophthalmic solutions. In 2024, its consolidated sales reached 231.8 billion won, a 9.9% increase from the previous year, with its subsidiary Optus Pharmaceuticals reporting a 6.4% rise in sales to 87.16 billion won.

Number of Employees

436people

Average Salary

65.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

734.96Industry Average 11.230.0Point

65.4x industry avg (risky)

PBR

10.72Industry Average 0.810.0Point

13.2x industry avg (risky)

ROE

3.37Industry Average 4.012.5Point

Below industry avg

Debt Ratio

25.05Industry Average 12.430.0Point

2.0x industry avg (risky)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲9.7% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲74.1% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 0.1% (improving, 3yr)

Detailed News Sentiment

25 totalPositive 10Neutral 5Negative 10Average Sentiment Score 73.2

Negative
SK하닉 미수로 3200만원 잃고 "돈 빌려달라"더니…삼천당제약에 또 ...
SK하닉의 미수금 문제로 삼천당제약 투자자들이 손실을 입고 불안감이 증가하고 있다.
Neutral
삼천당제약 “日 진출 방안 논의”…규제당국 험난한 문턱 넘어야
삼천당제약의 일본 진출 논의에도 불구하고, 현재로서는 허가 신청 단계가 아니며 규제 장벽이 존재해 불확실성이 높다.
Positive
삼천당제약 "FDA Pre-ANDA 결과 바탕으로 日 사업 본격화"
삼천당제약은 FDA의 긍정적인 Pre-ANDA 답변을 바탕으로 일본 시장 진출을 본격화하며 긍정적인 전망을 보이고 있다.

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 166,100Won52-week high 1,184,00052-week low 152,800

1-month return0.0Point

1m -30.36% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-07-23
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-06-30
Neutral임시주주총회결과2026-06-30